Fig. 3: Time to neutrophil (A) and platelet recovery (B) at the end of cycle 1 with doublet vs. triplet regimens. | Blood Cancer Journal

Fig. 3: Time to neutrophil (A) and platelet recovery (B) at the end of cycle 1 with doublet vs. triplet regimens.

From: Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Fig. 3

A The median time to absolute neutrophil count (ANC) > 500/mm3 is 21 days (95% CI: 16–46 days) in the doublet group and 40 days (95% CI: 33–48 days) in the triplet group, HR 1.68 (95% CI: 0.83–3.41), p = 0.15. B The median time to platelet > 50,000 microliter is 25 days (95% CI: 22–53 days) in the doublet group and 29 days (95% CI: 23–41 days) in the triplet group. HR 0.84 (95% CI: 0.41–1.72), p = 0.6. ANC absolute neutrophil count (per mm3); Platelet (per microliter); 50k, 50,000.

Back to article page